Pasar al contenido principal

Pablo Velasco Puyó

I have been an medical physician in the Pediatric Oncology and Hematology Service since 2012. My medical and research activity focuses primarily on sickle cell disease and pediatric acute lymphoblastic leukemia.

Instituciones de las que forman parte

Investigador/a principal
Cáncer y Enfermedades Hematológicas Infantiles
Vall Hebron Institut de Recerca
Médico
Oncología y Hematología Pediátrica
Hospital Infantil i Hospital de la Mujer
Pablo Velasco Puyó

Pablo Velasco Puyó

Pablo Velasco Puyó

Instituciones de las que forman parte

Investigador/a principal
Cáncer y Enfermedades Hematológicas Infantiles
Vall Hebron Institut de Recerca
Médico
Oncología y Hematología Pediátrica
Hospital Infantil i Hospital de la Mujer

I have been an medical physician in the Pediatric Oncology and Hematology Service since 2012. My medical and research activity focuses primarily on sickle cell disease and pediatric acute lymphoblastic leukemia.

During my professional career I have tried to develop a comprehensive care of these diseases, with the direct assistance of patients, as well as with clinical and translational research, including direct work in the laboratory, participation in 12 clinical trials as principal investigator or subinvestigator, and the publication of 17 scientific articles and 1 book chapter, related to these diseases.
 
- At the teaching level I am an associate professor at the Faculty of Medicine of the Autonomous University of Barcelona, ​​I have participated in national and international conferences (59 as an author), in pediatric hematology courses and together with doctors and nurses of the department, we have created the first oncohematological emergency simulations in situ. We have also created, together with pediatric hematologists from different centers, the Working Group on Pediatric Hematology of the Catalan Society of Pediatrics, which I currently co-coordinate.
- In this difficult year of the COVID pandemic, concerned with understanding and adapting to the risk of our patients with SARS-CoV2, we have created the European COVID registry in the European reference network EurobloodNet, of which I am a principal investigator, and we have collaborated in the largest registry of pediatric oncology and COVID, the Global Registry of COVID-19 in Pediatric Cancer (StJude-SIOP). I am part of the national and international scientific groups SEHOP, SIOPE, Eurobloodnet, Spanish Cytology Club, SEHH, EHA
- But for global care it is necessary to develop initiatives focused on patients and their families from other perspectives, so we invented with Eunice Blanco, head of Social Work the Superbox device (new medical device to facilitate patient-friendly intravenous administration, more information at www.superbox.es) and I have participated in the formation of the Spanish association of patients with sickle cell disease ASAFE, of which I am part of the board of the association (https://www.asafefalciforme.org/). Giving patients a voice is a very valuable tool for healthcare professionals, a compass to indicate the right path for our actions.
- As a curiosity, I am also a veterinarian, it was during my training at L’Ecole Veterinaire de MAison Alfort in Paris, before year 2000, where I learned how much translational research between species can contribute to the understanding of oncology and the research of new treatments.
- I have also worked as an expatriate pediatrician in several countries in Africa, Guatemala and India, and I have been trained in the international Red Cross emergency team, with the conviction that health care should be global and equitable for all children.

Proyectos

Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders

IP: Lucas Moreno Martín-Retortillo
Colaboradores: Luís Gros Subias, Raquel Andreu Vilarroig, Andrea Vilaplana Blanes, Pablo Velasco Puyó, Laura Murillo Sanjuán , Nora Diéguez Martínez, Maria Isabel Benitez Carabante, Aroa Soriano Fernández, Guillem Pons Barcons, Jose Miguel Lizcano De Vega, Maria Cristina Díaz de Heredia Rubio, María de los Ángeles Rodríguez Sánchez, Maria Luz Uria Oficialdegui , Maria Jose Pérez García, Miguel Segura Ginard, M Mar Mañu Pereira, Lorena Valero Arrese, Raquel Anta Peña, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Anna Llort Sales, Elisabet Megías Roda, Raquel Hladun Alvaro, Ariadna Boloix Amenós, Carlota Aguilera Ordoñez, Adria Molero Valenzuela, Júlia Sansa Girona, Gabriela Guillén Burrieza, Laura Alonso Garcia , Victoria Gutierrez Valle, Idoia Bolinaga Ayala, Josep Roma Castanyer, Sergio Espinosa Gil, Gabriel Osvaldo Gallo , Elena Andretta , Roberta Antonelli , Claire Diot , Amira Idrizovic
Entidad financiadora: AGAUR no fer servir-correcte 4301-37
Financiación: 60000
Referencia: 2021 SGR 00638
Duración: 01/01/2022 - 31/12/2024

ENABLING PERSONALIZED MEDICINE OF SICKLE CELL DISEASE PATIENTS BASED ON INTEGRATIVE DIAGNOSIS OF NEW GENERATION METHODOLOGIES

IP: M Mar Mañu Pereira
Colaboradores: Pablo Velasco Puyó, Bárbara Tazón Vega, Maria Cristina Díaz de Heredia Rubio, Thaïs Murciano Carrillo, Victoria Gutierrez Valle, Amira Idrizovic
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 99220
Referencia: PI20/01454
Duración: 01/01/2021 - 31/12/2023

El papel oncogénico de las vías embrionarias (Notch, Hedgehog y Wnt) en el Rabdomiosarcoma: ampliando el conocimiento para descubrir nuevas dianas terapéuticas.

IP: Josep Roma Castanyer
Colaboradores: Soledad Gallego Melcón, Pablo Velasco Puyó, Anna Llort Sales
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 116765
Referencia: PI14/00647
Duración: 01/01/2015 - 31/12/2017

Red Temática de Investigación Cooperativa en Cáncer - RTICC

IP: Josep Sánchez de Toledo Codina
Colaboradores: Soledad Gallego Melcón, Luís Gros Subias, Pablo Velasco Puyó, Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Constantino Sábado Álvarez, Anna Llort Sales, Laura Alonso Garcia , Josep Roma Castanyer
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 186750
Referencia: RD12/0036/0016
Duración: 01/01/2013 - 30/06/2017

Noticias relacionadas

La reunión ha sido el punto de encuentro del grupo EpSSG dedicado a la investigación para mejorar el tratamiento de los sarcomas de partes blandas de la infancia y la adolescencia.

Las sesiones se centraron en compartir novedades sobre las técnicas de diagnóstico y de tratamiento de pacientes con esta enfermedad, presentar resultados del ensayo clínico de terapia génica y orientar a las familias sobre sus cuidados y seguimiento.

Los fondos se destinarán a la captación y retención de jóvenes talentos, así como al desarrollo de un nuevo fármaco epigenético.

Profesionales relacionados

José Alegre Martin

José Alegre Martin

Investigador/a principal
Reumatología
Leer más
Francisco Rodríguez Frias

Francisco Rodríguez Frias

Investigador/a principal
Bioquímica Clínica, Vehiculización de Fármacos y Terapia
Leer más
Montse Martinez Muñoz

Montse Martinez Muñoz

Leer más
Josep Sánchez de Toledo Codina

Josep Sánchez de Toledo Codina

Investigador/a principal
Cáncer y Enfermedades Hematológicas Infantiles
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.